Posted by Netch on October 9, 2007, at 18:08:37
In reply to Inovelon, posted by Quintal on October 9, 2007, at 16:38:23
Interesting... found this:
"Synosia Therapeutics today announced that it has signed an exclusive, worldwide licensing agreement (outside of Japan) with Novartis Pharma AG to develop and commercialise rufinamide for the treatment of anxiety disorders and bipolar mood disorders."
"Rufinamide was discovered and developed by Novartis, which granted certain licensing rights to Eisai of Japan in 2004. On January 16, 2007, Inovelon® (rufinamide) received marketing authorisation in the European Union as adjunctive therapy in Lennox-Gastaut Syndrome (LGS),a severe form of epilepsy that develops in early childhood. Eisai has also submitted an NDA for rufinamide to the US Food and Drug Administration (FDA) in November 2005 for adjunctive therapy in adults and adolescents (12 years of age and over). It received orphan drug status for LGS in October 2004. "
poster:Netch
thread:788111
URL: http://www.dr-bob.org/babble/20071009/msgs/788119.html